About This Show
As we continue the fight against heart disease and a range of other conditions, advances in cardiovascular care remain at the forefront of medicine. Featuring the latest developments in cardiology from the perspective of top experts, Heart Matters allows you to keep current on recent trends, promising new technologies, and key research findings relevant to your practice. The program is hosted by the following leaders of the American College of Cardiology: Dr. Jack Lewin, chief executive officer and Dr. Janet Wright, senior vice president for science and quality.
Most Recent Episode
Individualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE
Feb 7 16
Host: Jennifer Caudle, DO
Guest: Alok A. Khorana, M.D.
Join Prof. Alok Khorana as he is interviewed on the the place for direct oral anticoagulants in the individualization of VTE treatment and prevention of recurrence. This session will highlight the unique experience and therapeutic knowledge of Prof. Khorana, broadening listeners’ perspectives and enlightening new methods of treating, diagnosing and thinking about current medical issues related to VTE facing clinicians. Since the recording of this program, the 'Antithrombotic Therapy for VTE Disease: CHEST Guideline' (Kearon C, et al. CHEST 2016, doi: 10.1016/j.chest.2015.11.026) has been published online. Recommendations from the new guidelines have been incorporated into the visual presentation but are not reflected in the audio portion, and include the following: For VTE and no cancer, as long-term anticoagulant therapy, we suggest dabigatran (Grade 2B), rivaroxaban (Grade 2B), apixaban (Grade 2B) or edoxaban (Grade 2B) over VKA therapy, and suggest VKA therapy over LMWH (Grade 2C) For VTE and cancer, we suggest LMWH over VKA (Grade 2B), dabigatran (Grade 2C), rivaroxaban (Grade 2C), apixaban (Grade 2C) or edoxaban (Grade 2C)